Clinique des maladies lipidiques de Quebec Inc

Québec, Quebec G1V 4W2

0 studies enrolling now · 9 studies all time

What they study most

Atherosclerosis, Cardiovascular Diseases, Dyslipidemia, Familial Chylomicronemia Syndrome, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia, Hypertriglyceridemia, Severe Hypertriglyceridemia

Studies at this site

• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia — Completed
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia — Completed
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen — Running, not enrolling
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) — Running, not enrolling
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) — Completed
• A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins — Completed
• A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins — Completed
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia — Completed